As of the latest Form 4 filed Jul 9, 2026.
What Ironwood Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 29 most recent filings for IRWD.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | Silver Ronald PFO & PAO | SSale | −128K | $4.52 | $578K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Shepard Jay Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Kessler Marla L Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Currie Mark G Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Duane Jon R Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | DENNER ALEXANDER J Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | McHugh Julie Director | SSale | −21.6K | $3.73 | $80.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | McHugh Julie, Director | AAward | +63.5K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Moukheibir Catherine Director | AAward | +63.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | DENNER ALEXANDER J Director | AAward | +4.07K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Silver Ronald PFO & PAO | AAward | +25.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Gaskins Tammi L Chief Commercial Officer | AAward | +137K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Shetzline Michael SVP, CMO, Head-Res&Drug | AAward | +137K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Silver Ronald Principal Accounting Officer | AAward | +164K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | John Minardo Chief Legal Officer | AAward | +137K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Martini Gregory S. Chief Financial Officer | AAward | +137K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | MCCOURT Thomas A Chief Executive Officer | AAward | +410K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | Martini Gregory S. Chief Financial Officer | SSale | −11.5K | $3.66 | $41.9K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | John Minardo Chief Legal Officer | SSale | −19.1K | $3.66 | $69.7K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | Shetzline Michael SVP, CMO, Head-Res&Drug | SSale | +17.0K | $3.66 | $62.3K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | Gaskins Tammi L Chief Commercial Officer | SSale | −11.2K | $3.66 | $41.1K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | MCCOURT Thomas A Chief Executive Officer | SSale | −104K | $3.66 | $379K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-24 | Silver Ronald Principal Accounting Officer | SSale | −12.6K | $3.66 | $46.2K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | Martini Gregory S. Chief Financial Officer | SSale | −10.5K | $3.81 | $40.0K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | John Minardo Chief Legal Officer | SSale | −17.4K | $3.81 | $66.4K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | Shetzline Michael SVP, CMO, Head-Res&Drug | SSale | −15.6K | $3.81 | $59.3K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | Gaskins Tammi L Chief Commercial Officer | SSale | −10.3K | $3.81 | $39.2K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | MCCOURT Thomas A Chief Executive Officer | SSale | −94.8K | $3.81 | $361K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | Silver Ronald Principal Accounting Officer | SSale | −11.6K | $3.81 | $44.0K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IRWD’s full analysis or the market-wide insider trading feed. The tabs above jump to IRWD’s other SEC data.
Source: SEC Form 4 filings for IRWD, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.